PPARA and metabolic dysfunction-associated steatotic liver disease: Furthermore, PPARα agonists can increase the stability of atherosclerotic plaques and reduce the accumulation of hepatic fat accumulation, leading the party to NASH/NAFLD and reducing the risk of CVD.